Medical and Psychiatric Effects of Long-Term Dependence on High Dose of tramadol

El-Hadidy, Mohamed Adel; Helaly, Ahmed M.N.

doi:10.3109/10826084.2014.991406

Cited by 32 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La prescripción de tramadol en gotas sin indicar los milígramos a administrar fue una práctica frecuente en esta muestra, cuyas posibles repercu-siones podrían impactar la seguridad y efectividad del tratamiento del paciente y el sistema de salud. La preocupación por la ocurrencia de EA debido a tramadol ya fue puesta en alerta por el Instituto de Salud Pública de Chile el año 2010 8 .…”

Section: Discussionunclassified

Prescripción de opioides al alta de un servicio de urgencia

et al. 2017

View full text Add to dashboard Cite

Background There is a worrisome increase in opioid prescription worldwide. Their use and overuse may cause adverse outcomes. Aim To determine incidence and characteristics of opioid prescription at discharge at an emergency department (ED). Material and Methods A prospective observational study in a random sample of adult patients attended at an ED of a teaching hospital. We reviewed medical records prescriptions for each patient to collect information about drugs prescribed, reason and medical indication of use (doses and duration). Results A total of 1,001 patients aged 50 ± 20 years (61% women) were studied. Seven percent of patients received an opioid prescription at discharge from the ED, mainly to treat renal and back pain. The dose, duration of treatments or both were incompletely described in 54% of prescriptions. The dose of tramadol in drops was incomplete in 96% of prescriptions. Conclusions Seven percent of patients discharged from an ED received an opioid prescription, mainly to treat non-oncological acute pain. The lack of information detected in the prescriptions affected quality, safety and effectiveness of the treatment, especially when pharmaceutical formulations were drops.

show abstract

Section: Discussionunclassified

Prescripción de opioides al alta de un servicio de urgencia

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefore, chronic pain itself may set the stage to make a patient more likely to perceive opioids as rewarding and thus addictive [98]. However, in the case of tramadol [98][99][100] and buprenorphine [98,101] the risk of addiction might be lower than other opioids.…”

Section: Long-term Use Of Tramadol and Buprenorphine In Relieving Symmentioning

confidence: 99%

“…It seems that tramadol-dependence dose is more important than duration of use [99]. Tramadol may also have a relatively lower potential for abuse than…”

Section: Long-term Use Of Tramadol and Buprenorphine In Relieving Symmentioning

confidence: 99%

Coexistence of Chronic Pain and Depression: A Short Review with a Focus on the Antidepressant Effect of Tramadol and Buprenorphine

Szkutnik-Fiedler¹,

Grześkowiak²

2018

Neuropsychiatry

View full text Add to dashboard Cite

It is known that there is a strong relationship between chronic pain and depression, and both of these diseases can intensify each other. In addition to mental illnesses, there are also a number of somatic symptoms, including pain. While pain, especially chronic, is always associated with mental suffering, which can aggravate the symptoms of depression. Proper and timely identification of coexistence of these conditions allows for effective and safe pharmacotherapy.This article reviews the literature on the coexistence of chronic pain and depressive disorders. The common mechanisms of both these diseases and the frequency of their coexistence have been described. The results of studies on the problem of treatment of patients with chronic pain with concomitant depression and patients with depression declaring pain are presented. The role of tramadol and buprenorphine in relieving symptoms of depression, including severe and refractory to traditional treatment, has also been described.

show abstract

“…Tramadol is another increasingly popular drug of abuse (Randall and Crane 2014;El-Hadidy and Helaly 2015), a centrally acting analgesic used worldwide for the treatment of moderate to severe pain in acute or chronic conditions. It is atypical synthetic opioid (4-phenylpiperidine analog of codeine) with selectivity for the μ-opioid receptor (Grond and Sablotzki 2004).…”

Section: Introductionmentioning

confidence: 99%

“…It is atypical synthetic opioid (4-phenylpiperidine analog of codeine) with selectivity for the μ-opioid receptor (Grond and Sablotzki 2004). Little data exists as regards the neurotoxicity of tramadol, but an increase in deaths was, however, noted (Randall and Crane 2014) and high doses are associated with an increase in symptoms of anxiety, depression, and obsessive-compulsive neurosis as well as in hostile and aggressive behavior (El-Hadidy and Helaly 2015).…”

Section: Introductionmentioning

confidence: 99%

Identification of biomarkers for the detection of subtle brain injury after cannabis and/or tramadol administration

Abdel-Salam

Sleem

Youness

et al. 2019

Egypt J Forensic Sci

View full text Add to dashboard Cite

Background: There is a need to identify biomarkers which could indicate the occurrence of brain injury in drug abuse.Objectives: We aimed to investigate ubiquitin-C-terminal hydrolase-1 (UCH-L1), a neuronal cell body injury marker, the glial protein S-100 beta (S100β), and the glial fibrillary acidic protein (GFAP) as putative markers for neuronal injury due to cannabis, tramadol, or their combined use. Materials and methods: Rats were treated with cannabis and/or tramadol subcutaneously daily for 6 weeks and UCH-L1, S100β, and GFAP were immunoassayed in the brain and serum.Results: The results are as follows: (i) either cannabis or tramadol increased UCH-L1 and GFAP in the brain, (ii) serum UCH-L1 and GFAP increased by the highest dose of cannabis or tramadol, (iii) there was no additive effect for cannabis and tramadol on UCH-L1 or GFAP level in the brain or serum, (iv) S100β decreased in the brain by 5-20 mg/kg of cannabis and in the serum following 20 mg/kg of cannabis, and (v) S100β levels increased in the brain after 20 mg/kg of tramadol but decreased the brain and serum after both cannabis and tramadol. Cytoplasmic vacuolations, apoptotic cells, and gliosis were observed in the brain tissue of cannabis and/or tramadol-treated rats. Conclusions: These results suggest that changes in UCH-L1, GFAP, or S100β are likely to reflect neurotoxicity and serum levels could be used to detect neuronal damage in chronic users.

show abstract

Medical and Psychiatric Effects of Long-Term Dependence on High Dose of tramadol

Abstract: Tramadol dependence on high dose could be physically safe to some limit, but psychiatrically it has many side effects.

Cited by 32 publications

References 29 publications

Prescripción de opioides al alta de un servicio de urgencia

Prescripción de opioides al alta de un servicio de urgencia

Coexistence of Chronic Pain and Depression: A Short Review with a Focus on the Antidepressant Effect of Tramadol and Buprenorphine

Identification of biomarkers for the detection of subtle brain injury after cannabis and/or tramadol administration

Contact Info

Product

Resources

About